Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > REGULATORY
REGULATORY
- MHLW Releases Discussion Outline of ICH Lisbon Meeting
December 18, 2014
- LDP Tax Panel Execs Eye Slight Cut of R&D Tax Deduction Cap
December 17, 2014
- Drug Makers Present Cases in Which PI Trials in Japanese Could Be Omitted in Multinational Studies: PMDA Workshop
December 17, 2014
- Japan Tax Reform Plan Will Be Compiled by Year-End: Abe
December 16, 2014
- Editor’s Pick: Five Healthcare News Headlines for Dec. 1 - 14
December 15, 2014
- JPMA Will Work to Secure Quality, Transparency of Clinical Research for Purpose of Advertising: Vice President
December 15, 2014
- LDP Healthcare Big Names Cruise to Victory in Lower House Poll
December 15, 2014
- Panel Reveals Final Report Calling for Legal Regulations for Clinical Research
December 12, 2014
- Outline of New Global Clinical Trial Guidelines Agreed On at ICH Confab in Lisbon
December 12, 2014
- Elplat, Elaspol Generics to Join NHI Price List on Dec. 12
December 11, 2014
- Wholesalers’ Negative Primary Margin on Sales Widens Slightly in First Half of FY2014: Ryukaikon
December 11, 2014
- Ryukaikon Members Hail High Price Settlements, but Fret over Fallout from Penalty Fee Cuts
December 11, 2014
- Annual NHI Price Cuts Draw Fire from All Sides at Ryukaikon Council
December 10, 2014
- Eculizumab, Bosentan Designated as Orphan Drugs
December 10, 2014
- Japan NIH to Have Drug Discovery Support Unit
December 9, 2014
- Paclitaxel OK’ed for External Review under Fast-Track Senshin-Iryo Scheme for Cancer Drugs
December 8, 2014
- Five SGLT-2 Inhibitors Undergoing Evaluation for Risk of Dehydration: PMDA
December 8, 2014
- Fee Cut Rule Needs Review before Debate on Annual NHI Price Revisions: MHLW Exec
December 4, 2014
- LDP Members Share Various Opinions on Social Security Issues
December 4, 2014
- Council Approves Subsidies for Retreatment with 3-Drug Combination Therapies Using Protease Inhibitors Other than Simeprevir
December 4, 2014
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…